GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (ASX:RMD) » Definitions » Cyclically Adjusted FCF per Share

ResMed (ASX:RMD) Cyclically Adjusted FCF per Share : A$0.62 (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is ResMed Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ResMed's adjusted free cash flow per share for the three months ended in Mar. 2024 was A$0.392. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is A$0.62 for the trailing ten years ended in Mar. 2024.

During the past 12 months, ResMed's average Cyclically Adjusted FCF Growth Rate was 14.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ResMed was 100.00% per year. The lowest was 8.30% per year. And the median was 20.70% per year.

As of today (2024-05-17), ResMed's current stock price is A$32.78. ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was A$0.62. ResMed's Cyclically Adjusted Price-to-FCF of today is 52.87.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 34.18. And the median was 50.64.


ResMed Cyclically Adjusted FCF per Share Historical Data

The historical data trend for ResMed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cyclically Adjusted FCF per Share Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.40 0.43 0.49 0.53

ResMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.53 0.59 0.56 0.62

Competitive Comparison of ResMed's Cyclically Adjusted FCF per Share

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted Price-to-FCF falls into.



ResMed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.392/131.7762*131.7762
=0.392

Current CPI (Mar. 2024) = 131.7762.

ResMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.070 100.560 0.092
201409 0.049 100.428 0.064
201412 0.072 99.070 0.096
201503 0.071 99.621 0.094
201506 0.077 100.684 0.101
201509 0.105 100.392 0.138
201512 0.135 99.792 0.178
201603 0.103 100.470 0.135
201606 0.120 101.688 0.156
201609 0.064 101.861 0.083
201612 0.099 101.863 0.128
201703 0.047 102.862 0.060
201706 0.111 103.349 0.142
201709 0.066 104.136 0.084
201712 0.104 104.011 0.132
201803 0.120 105.290 0.150
201806 0.101 106.317 0.125
201809 0.031 106.507 0.038
201812 0.105 105.998 0.131
201903 0.120 107.251 0.147
201906 0.117 108.070 0.143
201909 0.139 108.329 0.169
201912 0.042 108.420 0.051
202003 0.229 108.902 0.277
202006 0.306 108.767 0.371
202009 0.119 109.815 0.143
202012 0.120 109.897 0.144
202103 0.149 111.754 0.176
202106 0.175 114.631 0.201
202109 -0.091 115.734 -0.104
202112 0.171 117.630 0.192
202203 0.060 121.301 0.065
202206 0.046 125.017 0.048
202209 0.013 125.227 0.014
202212 0.097 125.222 0.102
202303 0.255 127.348 0.264
202306 0.201 128.729 0.206
202309 0.259 129.860 0.263
202312 0.251 129.419 0.256
202403 0.392 131.776 0.392

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


ResMed  (ASX:RMD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ResMed's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=32.78/0.62
=52.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 34.18. And the median was 50.64.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ResMed Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (ASX:RMD) Business Description

Traded in Other Exchanges
Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.